Rectal Neoplasms Clinical Trial
Official title:
Robotic Transanal Specimen Extraction Surgery Versus Robotic Transabdominal Incision Specimen Extraction Surgery for Patients With Rectal Cancer: A Multicenter Randomized Controlled Trial
Verified date | July 2022 |
Source | The First Affiliated Hospital of Nanchang University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This prospective, multicenter, randomized, open-label study aims to evaluate the perioperative safety and feasibility of specimen extraction through anus regarding robotic radical excision of rectal cancer.
Status | Not yet recruiting |
Enrollment | 556 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age between 18 to 75 years; 2. Historically confirmed rectal adenocarcinoma; 3. Diagnosed with rectal cancer by pelvic/rectal magnetic resonance imaging; 4. cT1-4aNxM0 high rectal adenocarcinoma; cT1-3NxM0 mid/low rectal adenocarcinoma; 5. No evidence of distant metastases; 6. A maximum of 5cm in diameter; 7. Body mass index (BMI) = 30 kg / m2; 8. No local complications (no obstruction, incomplete obstruction, no massive active bleeding, no perforation, preoperatively abscess formation, no local invasion); 9. Willing to undergo surgery; 10. Sign the informed consent; Exclusion Criteria: 1. Presence of lateral/inguinal lymph node metastases; 2. Previous history of malignant colorectal tumor; 3. Multiple primary colorectal tumors; 4. Neoadjuvant therapy; 5. Salvage surgery for endoscopic surgery; 6. History of previous abdominopelvic surgeries or extensive intra-abdominal adhesion; 7. Familial adenomatous polyposis, Lynch syndrome, and inflammatory bowel disease; 8. Comorbid with other malignancies within 5 years; 9. ASA = IV and/or ECOG performance status score = 2; 10. Severe liver, kidney, cardiopulmonary insufficiency, coagulopathy or serious underlying diseases; 11. Serious mental illness; 12. Pregnant or lactating women; 13. Uncontrolled infection; 14. Abnormal anal function or anal stenosis; |
Country | Name | City | State |
---|---|---|---|
China | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing | |
China | The Second Xiangya Hospital, Central South University | Changsha | |
China | Three Gorges Hospital Affiliated to Chongqing University | Chongqing | |
China | Fujian Cancer Hospital | Fuzhou | |
China | The First Affiliated Hospital of Gannan Medical University | Ganzhou | |
China | The Second Affiliated Hospital, Sun Yat-sen University | Guangzhou | |
China | The Second Affiliated Hospital of Harbin Medical University | Harbin | |
China | The First Affiliated Hospital of Nanchang University | Nanchang | |
China | Zhongshan Hospital, Fudan University | Shanghai | |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | |
China | Zhongshan Hospital of Xiamen University | Xiamen | |
China | The First Affiliated Hospital of Zhengzhou University | Zhengzhou |
Lead Sponsor | Collaborator |
---|---|
Taiyuan Li |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complication rate | Complication rate within 1 month postoperatively.All complications of surgery will be documented and graded by the Clavien-Dindo classification system,generally including anastomotic leakage, abdominal infection, bleeding, incision infection, incision implantation, intestinal obstruction, and rectovaginal fistula. | Up to 30 days postoperatively. | |
Secondary | C-reactive protein (CRP) | Detection of serum CRP levels (mg/L) to evaluate surgical stress response and immune function. | 1 day before operation, 1, 3, 5 days postoperatively, and up to 2 weeks. | |
Secondary | Interleukin | Detection of serum levels of Interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) (pg/L) to evaluate surgical stress response and immune function. | 1 day before operation, 1, 3, 5 days postoperatively, and up to 2 weeks. | |
Secondary | Cortisol | Detection of Serum Cortisol Level (nmol/L) to evaluate surgical stress response and immune function. | 1 day before operation, 1, 3, 5 days postoperatively, and up to 2 weeks. | |
Secondary | CD3, CD4, and CD8 lymphocyte subsets | Count CD3, CD4, and CD8 lymphocyte subsets (pieces/ul) to assess surgical stress response and immune function. | 1 day before operation, 1, 3, 5 days postoperatively, and up to 2 weeks. | |
Secondary | Positive rate of tumor cells | Intraoperative peritoneal lavage fluid will be collected both for aerobic culture and centrifuged ,stained and viewed to find exfoliated cancer cells.The sample will be considered positive if at least one tumor cell was detected. | Intraoperative. | |
Secondary | bacterial positive rate | Intraoperative peritoneal lavage fluid will be collected both for aerobic culture and centrifuged ,stained and viewed to find exfoliated cancer cells.The sample will be considered positive if at least one tumor cell was detected. | Intraoperative. | |
Secondary | Pain assessment | Visual analogue scale (VAS) will be used to evaluate the postoperative pain. If analgesics were needed, the type and dose of analgesics after operation should be recorded. | 1 day before operation, 1, 2, 3 days postoperatively, and up to 2 weeks. | |
Secondary | Wexner scale | Wexner scale (0 are normal continence, 20 are maximum incontinence with maximum disturbance of lifestyle) will be used to evaluate the defecation function. | 1 day before operation, and 1, 3, 6 months postoperatively. | |
Secondary | LARS scale | LARS scale(0~20 points are defined as no LARS, Scores from 21 to 29 were defined as mild LARS, and from 30 to 42 as severe LARS. The higher the score, the worse the anal bowel function) will be used to evaluate the defecation function. | 1 day before operation, and 1, 3, 6 months postoperatively. | |
Secondary | Postoperative recovery composite | Including the time to first flatus (record the patient's first self induced exhaust time after operation, accurate to hours, and perform auscultation of bowel sounds regularly every day after operation), the time to first ambulation (hours), the time to first eating (hours) and the time to first defecation (hours). | Up to 2 weeks. | |
Secondary | EORTC QLQ-C30 | To assess the quality of life of all cancer patients. | 1 day before operation, 1, 3, 6 months postoperatively. | |
Secondary | EORTC QLQ-C38 | To assess the quality of life in patients with rectal cancer. | 1 day before operation, 1, 3, 6 months postoperatively. | |
Secondary | Tumor size | To assess the quality of surgical specimens. | Up to 30 days postoperatively. | |
Secondary | Number of Histopathological type | To assess the quality of surgical specimens and postoperative pathological evaluation. | Up to 30 days postoperatively. | |
Secondary | Degree of differentiation | To assess the quality of surgical specimens and postoperative pathological evaluation. | Up to 30 days postoperatively. | |
Secondary | Distance , positive condition of pathological margin (proximal, distal, circumferential) | To assess the quality of surgical specimens and postoperative pathological evaluation. | Up to 30 days postoperatively. | |
Secondary | Number of lymph node dissection and metastasis | To assess the quality of surgical specimens and postoperative pathological evaluation. | Up to 30 days postoperatively. | |
Secondary | Nerve vessel involvement rate | To assess the quality of surgical specimens and postoperative pathological evaluation. | Up to 30 days postoperatively. | |
Secondary | Hospitalization costs | To assess the financial burden difference. | Up to 30 days. | |
Secondary | Local recurrence rate | To assess the long-term postoperative outcomes. | 1, 3, 5 years postoperatively. | |
Secondary | The incidence rate of distant metastasis | To assess the long-term postoperative outcomes. | 1, 3, 5 years postoperatively. | |
Secondary | Tumor-free survival rates | To assess the long-term postoperative outcomes. | 1, 3, 5 years postoperatively. | |
Secondary | Overall survival rate | To assess the long-term postoperative outcomes. | 1, 3, 5 years postoperatively. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537340 -
PET/MR for Staging Rectal Cancer Patients With and Without EMVI-MR
|
||
Recruiting |
NCT02565667 -
A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler
|
N/A | |
Terminated |
NCT02538913 -
Exercise Training for Rectal Cancer Patients
|
N/A | |
Not yet recruiting |
NCT02439086 -
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
|
N/A | |
Completed |
NCT02233374 -
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
|
N/A | |
Completed |
NCT00535652 -
Concentration of Ertapenem in Colorectal Tissue
|
Phase 4 | |
Completed |
NCT00535041 -
Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA
|
N/A | |
Recruiting |
NCT04949646 -
Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision
|
N/A | |
Recruiting |
NCT04095468 -
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
|
||
Recruiting |
NCT06017583 -
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT05689775 -
Reconstruction After Abdominoperineal Resection With Robot-assisted Harvest of VRAM Flap
|
||
Recruiting |
NCT04006951 -
Development of a Clinical and Biological Database in Rectum Cancer
|
N/A | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03714490 -
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03325361 -
The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage
|
N/A | |
Completed |
NCT02252250 -
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
|
N/A | |
Completed |
NCT01816607 -
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
|
||
Completed |
NCT04455737 -
Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision
|
||
Completed |
NCT01721785 -
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT01171300 -
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
|
N/A |